Adaptive Biotechnologies logo

ADPT - Adaptive Biotechnologies Share Price

$34.54 0.9  2.7%

Last Trade - 14/05/21

Large Cap
Market Cap £3.44bn
Enterprise Value £2.93bn
Revenue £82.2m
Position in Universe 1420th / 6846
Unlock ADPT Revenue
Relative Strength (%)
1m -17.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 38.4 55.7 85.1 98.4 150.3 218.1 +36.8%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AdaptiveBiotechnologies Corp revenues increased 84% to $38.4M. Netloss increased 29% to $40.6M. Revenues reflect Developmentrevenue segment increase from $11.4M to $23.3M, Sequencingrevenue segment increase of 60% to $15.2M. Higher net lossreflects Research and development - Balancing val increaseof 38% to $30.9M (expense), Sales and marketing - Balancingvalue increase of 41% to $18.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ADPT Revenue Unlock ADPT Revenue

Net Income

ADPT Net Income Unlock ADPT Revenue

Normalised EPS

ADPT Normalised EPS Unlock ADPT Revenue

PE Ratio Range

ADPT PE Ratio Range Unlock ADPT Revenue

Dividend Yield Range

ADPT Dividend Yield Range Unlock ADPT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ADPT EPS Forecasts Unlock ADPT Revenue
Profile Summary

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated September 8, 2009
Public Since June 27, 2019
No. of Shareholders: 117
No. of Employees: 622
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 140,311,141
Free Float (0.0%)
Eligible for
ADPT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ADPT
Upcoming Events for ADPT
Friday 11th June, 2021
Adaptive Biotechnologies Corp Annual Shareholders Meeting
Friday 11th June, 2021 Estimate
Adaptive Biotechnologies Corp Annual Shareholders Meeting
Monday 9th August, 2021 Estimate
Q2 2021 Adaptive Biotechnologies Corp Earnings Release
Monday 8th November, 2021 Estimate
Q3 2021 Adaptive Biotechnologies Corp Earnings Release
Frequently Asked Questions for Adaptive Biotechnologies
What is the Adaptive Biotechnologies share price?

As of 14/05/21, shares in Adaptive Biotechnologies are trading at $34.54, giving the company a market capitalisation of £3.44bn. This share price information is delayed by 15 minutes.

How has the Adaptive Biotechnologies share price performed this year?

Shares in Adaptive Biotechnologies are currently trading at $34.54 and the price has moved by 1.38% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Adaptive Biotechnologies price has moved by -29.41% over the past year.

What are the analyst and broker recommendations for Adaptive Biotechnologies?

There are no analysts currently covering Adaptive Biotechnologies.

When will Adaptive Biotechnologies next release its financial results?

Adaptive Biotechnologies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Adaptive Biotechnologies dividend yield?

Adaptive Biotechnologies does not currently pay a dividend.

Does Adaptive Biotechnologies pay a dividend?

Adaptive Biotechnologies does not currently pay a dividend.

When does Adaptive Biotechnologies next pay dividends?

Adaptive Biotechnologies does not currently pay a dividend.

How do I buy Adaptive Biotechnologies shares?

To buy shares in Adaptive Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Adaptive Biotechnologies?

Shares in Adaptive Biotechnologies are currently trading at $34.54, giving the company a market capitalisation of £3.44bn.

Where are Adaptive Biotechnologies shares listed? Where are Adaptive Biotechnologies shares listed?

Here are the trading details for Adaptive Biotechnologies:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ADPT
What kind of share is Adaptive Biotechnologies?

Based on an overall assessment of its quality, value and momentum, Adaptive Biotechnologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Adaptive Biotechnologies share price forecast 2021?

Shares in Adaptive Biotechnologies are currently priced at $34.54. At that level they are trading at 77.19% discount to the analyst consensus target price of 0.00.

Analysts covering Adaptive Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -1.652 for the next financial year.

How can I tell whether the Adaptive Biotechnologies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptive Biotechnologies. Over the past six months, the relative strength of its shares against the market has been -37.96%. At the current price of $34.54, shares in Adaptive Biotechnologies are trading at -28.62% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Adaptive Biotechnologies PE Ratio?

We were not able to find PE ratio data for Adaptive Biotechnologies.

Who are the key directors of Adaptive Biotechnologies?

Adaptive Biotechnologies's management team is headed by:

Chad Robins - CHM
Harlan Robins - CFD
Nancy Hill - SVP
Julie Rubinstein - PRE
Chad Cohen - CFO
Francis Lo - CHO
Sharon Benzeno - SVP
Kevin Conroy - IND
Michelle Griffin - IND
Robert Hershberg - IND
Peter Neupert - LED
Stacy Taylor - SVP
Mark Adams - COO
Jyoti Palaniappan - SVP
Katey Owen - IND
Who are the major shareholders of Adaptive Biotechnologies?

Here are the top five shareholders of Adaptive Biotechnologies based on the size of their shareholding:

Viking Global Investors LP Hedge Fund
Percentage owned: 21.38% (30.0m shares)
Matrix Capital Management Company, LP Investment Advisor/Hedge Fund
Percentage owned: 9.35% (13.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.14% (10.0m shares)
T. Rowe Price New Horizons Fund Mutual Fund
Percentage owned: 4.29% (6.01m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 4.24% (5.95m shares)
Similar to ADPT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.